A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects

References

• Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet. 2015;386(9991):376–14. PMID: 25748615. doi:10.1016/s0140-6736(14)60802-3.
   PubMed Web of Science ®Google Scholar
• Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the third national health and nutrition examination survey 1991-94. J Rheumatol. 2006;33(11):2271–79. PMID: 17013996
   PubMed Web of Science ®Google Scholar
• Kidd BL, Langford RM, Wodehouse T. Arthritis and pain. Current approaches in the treatment of arthritic pain. Arthritis Res Ther. 2007;9(3):214–214. PMID: 17572915. doi:10.1186/ar2147.
   PubMed Web of Science ®Google Scholar
• Hochman JR, French MR, Bermingham SL, Hawker GA. The nerve of osteoarthritis pain. Arthritis Care Res (Hoboken). 2010;62(7):1019–23. PMID: 20589688. doi:10.1002/acr.20142.
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154–62. PMID: 3306916. doi:10.1126/science.3306916.
   PubMed Web of Science ®Google Scholar
• Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91. PMID: 16376998. doi:10.1016/j.tips.2005.12.001.
   PubMed Web of Science ®Google Scholar
• Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL, Warner DS. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189–204. PMID: 21602663. doi:10.1097/ALN.0b013e31821b1ac5.
   PubMed Web of Science ®Google Scholar
• Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Fransès RE, Mapp PI, Wilson D. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(10):1852–61. PMID: 20581375. doi:10.1093/rheumatology/keq188.
   PubMed Web of Science ®Google Scholar
• Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22(6):349–59. PMID: 18998753. doi:10.2165/0063030-200822060-00002.
   PubMed Web of Science ®Google Scholar
• Bradshaw RA, Murray-Rust J, Ibáñez CF, McDonald NQ, Lapatto R, Blundell TL. Nerve growth factor: structure/function relationships. Protein Sci. 1994;3(11):1901–13. PMID: 7703837. doi:10.1002/pro.5560031102.
   PubMed Web of Science ®Google Scholar
• Sánchez-Robles EM, Girón R, Paniagua N, Rodríguez-Rivera C, Pascual D, Goicoechea C. Monoclonal antibodies for chronic pain treatment: present and future. Int J Mol Sci. 2021;23(1):22. doi:10.3390/ijms221910325.
   PubMedGoogle Scholar
• Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996;13(4):485–88. PMID: 8696348. doi:10.1038/ng0896-485.
   PubMed Web of Science ®Google Scholar
• Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, Solders G, Holmgren G, Holmberg D, Holmberg M. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet. 2004;13(8):799–805. PMID: 14976160. doi:10.1093/hmg/ddh096.
   PubMed Web of Science ®Google Scholar
• Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368(6468):246–49. PMID: 8145823. doi:10.1038/368246a0.
   PubMed Web of Science ®Google Scholar
• Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, McMahon SB, Shelton DL, Levinson AD, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell. 1994;76(6):1001–11. PMID: 8137419.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Cash KA, McManus CD, Pampati V, Benyamin RM. Preliminary results of a randomized, doubleblind, controlled trial of fluoroscopic lumbar interlaminar epidural injections in managing chronic lumbar discogenic pain without disc herniation or radiculitis. Pain Physician. 2010;13(4;7):E279–292. PMID: 20648214. doi:10.36076/ppj.2010/13/E279.
   PubMed Web of Science ®Google Scholar
• Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. Jama. 2010;304(1):45–52. PMID: 20606148. doi:10.1001/jama.2010.893.
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–804. PMID: 20578811. doi:10.1517/14656566.2010.497720.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. Jama. 2019;322(1):37–48. PMID: 31265100. doi:10.1001/jama.2019.8044.
   PubMed Web of Science ®Google Scholar
• Moffat GJ, Retter MW, Kwon G, Loomis M, Hock MB, Hall C, Bussiere J, Lewis EM, Chellman GJ. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation. Birth Defects Res B Dev Reprod Toxicol. 2014;101(2):178–88. PMID: 24753333. doi:10.1002/bdrb.21105.
   PubMedGoogle Scholar
• Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S. Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis. Birth Defects Res B Dev Reprod Toxicol. 2013;98(6):459–85. PMID: 24391099. doi:10.1002/bdrb.21089.
   PubMedGoogle Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(Suppl 1):S15–23. PMID: 24687235. doi:10.1007/s40259-013-0064-z.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13(6):399–409. PMID: 17002967. doi:10.1080/10717540600814402.
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54(4):531–45. PMID: 12052713. doi:10.1016/s0169-409x(02)00026-1.
   PubMed Web of Science ®Google Scholar
• Nesbitt AM, Brown DT, Stephens S, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab’: 1119. Official J Am Coll Gastroenterol. | ACG. 2006;101:S438. doi:10.14309/00000434-200609001-01119.
   Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7:171–81. PMID: 18983497. doi:10.1111/j.1538-7836.2008.03212.x.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–39. PMID: 17686822.
   PubMed Web of Science ®Google Scholar
• Ishikawa G, Koya Y, Tanaka H, Nagakura Y. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis. Osteoarthritis Cartilage. 2015;23(6):925–32. PMID: 25677108. doi:10.1016/j.joca.2015.02.002.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Fujita M, Kawasaki S, Sanaki T, Yoshioka T, Higashino K, Tofukuji S, Yoneda S, Takahashi T, Koda K, et al. Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors. Pain. 2019;160(4):895–907. PMID: 30585984.
   PubMed Web of Science ®Google Scholar
• Xu L, Nwosu LN, Burston JJ, Millns PJ, Sagar DR, Mapp PI, Meesawatsom P, Li L, Bennett AJ, Walsh DA, et al. The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis Cartilage. 2016;24(9):1587–95. PMID: 27208420.
   PubMed Web of Science ®Google Scholar
• Salimi-Moosavi H, Rathanaswami P, Rajendran S, Toupikov M, Hill J. Rapid affinity measurement of protein-protein interactions in a microfluidic platform. Anal Biochem. 2012;426(2):134–41. PMID: 22542978. doi:10.1016/j.ab.2012.04.023.
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, Adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1–2):36–41. PMID: 19567252. doi:10.1016/j.jim.2009.06.009.
   PubMed Web of Science ®Google Scholar
• Weir N, Athwal D, Brown D, Foulkes R, Kollias G, Nesbitt A, Popplewell A, Spitali M, Stephens S. A new generation of high-affinity humanized PEGylated Fab [acute accent] fragment anti-tumor necrosis factor-[alpha] monoclonal antibodies. Therapy. 2006;3:535–45. accessed 27 Aug 2022. https://link.gale.com/apps/doc/A225319483/AONE?u=anon~27138985&sid=googleScholar&xid=3ac3c5e0.
   Google Scholar
• Masazumi K, Hirotsugu T, Yukari K, Jun T, Atsuo Y, Yoshimi E. inventors; Astellas Pharma, assignee. Novel anti-human NGF antibody. WO/2013/022083. 2013 Feb 14.
   Google Scholar
• Lambert B, Carron P, D’Asseler Y, Bacher K, Van den Bosch F, Elewaut D, Verbruggen G, Beyaert R, Dumolyn C, De Vos F. (99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res. 2016;6(1):88. PMID: 27957720. doi:10.1186/s13550-016-0245-0.
   PubMedGoogle Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–58. PMID: 16243265. doi:10.1016/s1359-6446(05)03575-0.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljeström M, Hukkanen M, Takagi M, Virtanen I, Santavirta S. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002;46(4):953–60. PMID: 11953972. doi:10.1002/art.10185.
   PubMedGoogle Scholar
• Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328–44. PMID: 19626656. doi:10.1002/bdrb.20201.
   PubMed Web of Science ®Google Scholar
• Johnson EM Jr., Gorin PD, Brandeis LD, Pearson J. Dorsal root ganglion neurons are destroyed by exposure in utero to maternal antibody to nerve growth factor. Science. 1980;210(4472):916–18. PMID: 7192014. doi:10.1126/science.7192014.
   PubMed Web of Science ®Google Scholar
• Yang W, Sung K, Zhou F, Xu W, Rissman RA, Ding J, Wu C. Targeted mutation (R100W) of the gene encoding NGF leads to deficits in the peripheral sensory nervous system. Front Aging Neurosci. 2018;10:373. PMID: 30524266. doi:10.3389/fnagi.2018.00373.
   PubMed Web of Science ®Google Scholar
• Glebova NO, Ginty DD. Heterogeneous requirement of NGF for sympathetic target innervation in vivo. J Neurosci. 2004;24(3):743–51. PMID: 14736860. doi:10.1523/jneurosci.4523-03.2004.
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22. PMID: 9051330. doi:10.1046/j.1468-2982.1997.1701015.x.
   PubMed Web of Science ®Google Scholar
• Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65(1):114–26. PMID: 23872058. doi:10.1016/j.ymeth.2013.06.035.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, Watts G, Hale G, Karagiannis SN. Fc-engineered antibodies with immune effector functions completely abolished. PLOS One. 2021;16(12):e0260954. PMID: 34932587. doi:10.1371/journal.pone.0260954.
   PubMed Web of Science ®Google Scholar
• Chen B, Vousden KA, Naiman B, Turman S, Sun H, Wang S, Vinall LMK, Kemp BP, Kasturiangan S, Rees DG, et al. Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses. Ann Rheum Dis. 2019;78(2):228–37. PMID: 30459279.
   PubMed Web of Science ®Google Scholar
• Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, Suematsu A, Suda T, Sato K, Takai T, et al. Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun. 2015;6(1):6637. PMID: 25824719.
   PubMedGoogle Scholar
• Chang MH, Nigrovic PA. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight. 2019;4(5). PMID: 30843881. doi:10.1172/jci.insight.125278.
   Web of Science ®Google Scholar
• Yu Y, Lu ST, Sun JP, Zhou W. Safety of low-dose tanezumab in the treatment of hip or knee osteoarthritis: a systemic review and meta-analysis of randomized phase iii clinical trials. Pain Med. 2021;22(3):585–95. PMID: 33141224. doi:10.1093/pm/pnaa260.
   PubMed Web of Science ®Google Scholar
• LaBranche TP, Bendele AM, Omura BC, Gropp KE, Hurst SI, Bagi CM, Cummings TR, Grantham LE 2nd, Shelton DL, Zorbas MA. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis. 2017;76(1):295–302. PMID: 27381034. doi:10.1136/annrheumdis-2015-208913.
   PubMed Web of Science ®Google Scholar
• Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem. 2001;299(2):119–29. PMID: 11730333. doi:10.1006/abio.2001.5380.
   PubMed Web of Science ®Google Scholar
• Tada M, Suzuki T, Ishii-Watabe A. Development and characterization of an anti-rituximab monoclonal antibody panel. MAbs. 2018;10(3):370–79. PMID: 29309213. doi:10.1080/19420862.2018.1424610.
   PubMed Web of Science ®Google Scholar
• Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. 1992;148(4):1149–54. PMID: 1737932
   PubMed Web of Science ®Google Scholar
• Buvanendran A, Kroin JS, Kari MR, Tuman KJ. A new knee surgery model in rats to evaluate functional measures of postoperative pain. Anesth Analg. 2008;107(1):300–08. PMID: 18635501. doi:10.1213/ane.0b013e3181732f21.
   PubMed Web of Science ®Google Scholar
• Matson DJ, Broom DC, Carson SR, Baldassari J, Kehne J, Cortright DN. Inflammation-induced reduction of spontaneous activity by adjuvant: a novel model to study the effect of analgesics in rats. J Pharmacol Exp Ther. 2007;320(1):194–201. PMID: 17050782. doi:10.1124/jpet.106.109736.
   PubMed Web of Science ®Google Scholar
• Takeshita N, Yoshimi E, Hatori C, Kumakura F, Seki N, Shimizu Y. Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents. J Pharmacol Sci. 2011;115(4):481–89. PMID: 21325780. doi:10.1254/jphs.10319fp.
   PubMed Web of Science ®Google Scholar